(MENAFN- Market Press Release) November 1, 2025 7:18 am - The global TNF-alpha Inhibitors for Crohn's Disease Market is projected to reach USD 12,500 million by 2025, growing at a 4.3% CAGR (2025-2032).

TNF-alpha Inhibitors for Crohn's Disease Market to Reach USD 12,500 Million by 2025, Driven by Increasing Biologic Adoption and Rising Crohn's Disease Prevalence

The global TNF-alpha Inhibitors for Crohn's Disease Market is projected to reach USD 12,500 million by 2025, expanding at a CAGR of 4.3% from 2025 to 2032. This steady growth is fueled by the rising prevalence of Crohn's disease, increased diagnosis rates, and a strong shift toward biologic therapies for long-term management. Advancements in monoclonal antibody technology and improved reimbursement frameworks in developed regions are further propelling market expansion. North America dominates the market, followed by Europe and Asia-Pacific, owing to high awareness levels, well-established healthcare infrastructure, and growing biologic drug availability in emerging economies.

Key Segment or Application Focus:

TNF-alpha inhibitors are primarily used for moderate to severe Crohn's disease cases that are unresponsive to conventional treatments. Among key drug classes, infliximab, adalimumab, and certolizumab pegol remain the most prescribed, driven by their proven efficacy in reducing intestinal inflammation and inducing remission. The hospital pharmacy segment leads distribution, supported by growing patient reliance on infusion-based therapies. Additionally, the self-administered subcutaneous formulations segment is expanding rapidly due to improved convenience, patient adherence, and telehealth support systems that enable at-home biologic management.

Price Trend:

The average global price for TNF-alpha inhibitors has shown a modest 1.8% increase from 2024 to 2025, primarily influenced by higher manufacturing costs and inflationary pressures across key raw materials. In the United States, prices remain among the highest, supported by robust biologics demand and extended patent protection for certain brands. Meanwhile, Germany and Japan have experienced stable pricing due to biosimilar competition and government-driven cost containment policies. However, newer formulations with enhanced dosing schedules have contributed to a gradual price rise in emerging markets, including China and India, where patient access to biologics is steadily improving.

Key Players Snapshot:

Leading pharmaceutical companies continue to dominate this segment through innovation and strong biologic portfolios. AbbVie Inc. (U.S.) remains a market leader with its blockbuster product Humira, while Johnson & Johnson (U.S.) offers Remicade and Simponi, strengthening its presence in both intravenous and subcutaneous categories. In Europe, UCB S.A. (Belgium) and Pfizer Inc. (U.S.) are key players offering biosimilars and next-generation TNF blockers. Emerging contributors such as Samsung Bioepis (South Korea) and Celltrion Healthcare (South Korea) are rapidly expanding their global biosimilar footprint, particularly across cost-sensitive markets. Together, these companies are shaping a competitive yet innovation-driven landscape for TNF-alpha inhibitors in Crohn's disease treatment.

Request for customization

MENAFN02112025003520003262ID1110281578